Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Bone Marrow Transplant

Fludarabine Followed by HCT for Primary Immunodeficiencies (FHCRC-2007)
Hematopoietic Cell Transplantation for Treatment of Patients with Primary Immunodeficiencies and Other Nonmalignant Inherited Disorders Using Low-dose TBI and Fludarabine With or Without Campath®
Status Conditions Phase Study ID
Open Immunodeficiency Syndromes
Severe Combined Immunodeficiency Syndrome (SCID)
Phase II FHCRC-2007
NCT00553098
Summary

The purpose of this study is to determine whether or not a non-myeloablative conditioning regimen followed by stem cell transplantation is safe and effective as treatment of non-malignant diseases of the blood and immune system. The chemotherapy and irradiation given just before a transplant is called the conditioning regimen. A non-myeloablative conditioning regimen uses lower doses of chemotherapy and radiation than a conventional conditioning regimen.

Most of the treatment will be given at the Seattle Cancer Care Alliance (SCCA) outpatient clinic. Initial in-hospital treatment will be given at the University of Washington Medical Center or Children?s Hospital and Regional Medical Center.

Treatment on the study will last about four months (about one month before the transplant and three months after the transplant), but could be longer. Participants may be asked to return for follow-up visits 6 months, and then every year, after the transplantation.

Additional bone marrow or blood samples may be drawn at various time points for up to five years after the transplant.


Investigator
Lauri Burroughs, MD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Age 54 years or younger.
  • Diagnosed with an immunodeficiency or other non-malignant disease that is treatable by allogeneic stem cell transplantation.
  • Patients with pre-existing medical conditions or other factors that rule out treatment with conventional myeloablative stem cell transplantation.

 

Other eligibility criteria may apply.

Exclusions (conditions that would prevent participation in this study)
  • Patients with Aplastic anemia and Fanconi anemia
  • 55 years or older
  • Patient has HIV
  • Patient is a female who is pregnant or breast-feeding

 

Other exclusion criteria may apply.

Last Updated
October 21, 2011
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.